Biopharmaceutical News and Research

RSS

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.

16 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

ATMI introduces new range of single-use bioprocess vessels

ATMI, Inc. today unveiled an important extension to its Integrity™ product line for the biopharmaceutical and biotechnology industries with the introduction of a new range of single-use bioprocess vessels (BPVs). The Integrity BPVs were launched at the IBC Single-Use Applications for Biopharmaceutical Manufacturing event, taking place now through Wednesday, June 16, 2010.

15 Jun 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

Comprehensive source for treatment information of atrial fibrillation in the European market

Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.

15 Jun 2010

Georgia Bioscience Commercialization Center launched

Lt. Governor Casey Cagle today joined Georgia Bio, the Georgia Research Alliance, the Metro Atlanta Chamber and the Innovation Crescent business community in announcing the launch of the Georgia Bioscience Commercialization Center (GBCC), which will act as a start-up catalyst and resource center for bioscience entrepreneurs in Georgia.

15 Jun 2010

Cangene third-quarter revenues decline 39% to $41.1M

Cangene Corporation today reports financial results for the third quarter ended April 30, 2010.

15 Jun 2010

ICON, PAREXEL to provide global support for execution of Bristol-Myers Squibb's clinical studies

Bristol-Myers Squibb Company today announced that it has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company's clinical development program.

From Parexel 15 Jun 2010

PAREXEL, Bristol-Myers Squibb establish strategic partnership in clinical development

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that Bristol-Myers Squibb, a global biopharmaceutical company, has established a strategic partnership with PAREXEL to enable greater effectiveness in clinical development.

From Parexel 14 Jun 2010

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

New Brunswick Scientific, an Eppendorf Company, and Pall Corporation today announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.

From Pall Corporation 14 Jun 2010

MP Biomedicals to acquire ICPbio International

MP Biomedicals LLC announced today that it has signed a definitive agreement to acquire the assets of ICPbio International LTD., an Auckland, New Zealand based protein biologics manufacturing company, subject to normal closing adjustments. This acquisition places MP Biomedicals in a strong position to pursue sales and distribution of serum protein products used in research and manufacturing in the Biopharmaceutical, In vitro diagnostic and Biotech sectors.

From MP Biomedicals, LLC 14 Jun 2010

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

14 Jun 2010

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc., a biopharmaceutical company, announced today that the National Science Foundation has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

UBC earns high ratings in 2010 late phase market dynamics survey

United BioSource Corporation (UBC) today announced results from an independent survey that examined late phase product development services delivered by 34 contract research organizations and other scientific and medical affairs companies serving the biopharmaceutical industry. The report, titled 2010 Late Phase Market Dynamics and published by Industry Standard Research (ISR), provided data and analysis from a survey that captured information from 149 respondents, representing 95 companies.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Biopharmaceutical News and Research

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

ATMI introduces new range of single-use bioprocess vessels

AMRI announces acquisition of Hyaluron

Comprehensive source for treatment information of atrial fibrillation in the European market

Georgia Bioscience Commercialization Center launched

Cangene third-quarter revenues decline 39% to $41.1M

ICON, PAREXEL to provide global support for execution of Bristol-Myers Squibb's clinical studies

PAREXEL, Bristol-Myers Squibb establish strategic partnership in clinical development

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

MP Biomedicals to acquire ICPbio International

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

UBC earns high ratings in 2010 late phase market dynamics survey

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Biotechnology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News